Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

A dose-escalation study of cisplatin (CDDP) combined with S-1, a new oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD), dose-limiting toxicities (DLTs), and objective response rate (RR) in advanced gas...

Descripción completa

Detalles Bibliográficos
Autores principales: Koizumi, W, Tanabe, S, Saigenji, K, Ohtsu, A, Boku, N, Nagashima, F, Shirao, K, Matsumura, Y, Gotoh, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395274/
https://www.ncbi.nlm.nih.gov/pubmed/14676796
http://dx.doi.org/10.1038/sj.bjc.6601413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395274/
https://www.ncbi.nlm.nih.gov/pubmed/14676796
http://dx.doi.org/10.1038/sj.bjc.6601413

Ejemplares similares